Global hormone replacement therapy market is expected to
reach USD 28.4 billion by 2022, according to a new report by Grand View
Research, Inc. Increasing geriatric and neonatal population base, growing cases
of hormonal imbalances, and large presence of unmet healthcare needs in
emerging economies are some vital impact rendering drivers.
Estrogen replacement therapy dominated the market in 2015.
Moreover, the rising number of women reaching the menopausal age is expected to
drive the demand for these treatments over the forecast period.
Furthermore, rise in premature births that lead to genital
disorders and slower rate of growth in these neonates are anticipated to fuel
the demand for growth hormone therapy. According to statistics provided by the
CDC, over 15 million babies were born preterm in 2014 annually. This number is
anticipated to rise over the next seven years and become a leading cause for
disabilities, illnesses, arrested development, and mortality.
To request a sample copy or view summary of this
report, click the link below:
http://www.grandviewresearch.com/industry-analysis/hormone-replacement-therapy-market
http://www.grandviewresearch.com/industry-analysis/hormone-replacement-therapy-market
Further key findings from the study suggest:
- Estrogen
therapy is expected to dominate the product segment and hold over 50.0% of
the market share by 2022. This growth can be attributed to the increasing
focus of healthcare bodies such as the Women’s Health Initiative, The
North America Menopause Society, and The British Menopause Society, on
providing safe replacement therapy.
- The
parenteral route of administration is commonly used for delivery of drugs
such as Nutropin, Signifor, Genotropin, and Tev-Tropin. Other routes such
as pen-based delivery systems and implants are gaining popularity owing to
higher patient comfort and ease-of-use. Furthermore, technological
advancements in the field providing higher bioavailability of drug and
needle-free administration are predicted to positively impact growth.
- Menopause
and their vasomotor symptoms are expected to be the most prevalent disease
over the forecast period owing to increasing number of women approaching
the menopausal age. The segment is predicted to hold about 40.0% of the
market share by 2022.
- North
America, particularly the U.S. dominated the market and held about 35.0%
of the total revenue in 2015. Existence of well-regulated healthcare
system and presence of a large pool of target population are a few factors
that promote growth. Countries such as South Africa, China, India, and
Brazil are anticipated to witness lucrative growth over the forecast
period, with China predicted to have the fastest growth of over 10.0%.
- Some
key companies catering to hormone replacement therapies include Pfizer,
Inc., Merck Serono, Novo Nordisk, Eli Lilly, Bayer Healthcare, Mylan
Laboratories, Amgen, Novartis, and Genentech. Introduction of new
formulations and development of innovative drug delivery systems are
expected to be a few initiatives taken by these players over the forecast
period.
Grand View Research has segmented the hormone replacement
therapy market on the basis of product, route of administration, disease type,
and region
Hormone Replacement Therapy Market Product Outlook
(Revenue, USD Million, 2012 - 2022)
- Estrogen
Replacement Therapy
- Human
Growth Hormone Replacement Therapy
- Thyroid
Replacement Therapy
- Other
Hormone Replacement Therapy Market Route Of
Administration Outlook (Revenue, USD Million, 2012 - 2022)
- Oral
- Parenteral
- Transdermal
- Other
Hormone Replacement Therapy Market Type Of Disease
Outlook (Revenue, USD Million, 2012 - 2022)
- Menopause
- Hypothyroidism
- Male
Hypogonadism
- Growth
Hormone Deficiency
- Other
Hormone Replacement Therapy Market Regional Outlook
(Revenue, USD Million, 2012 - 2022)
- North
America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia
Pacific
- Japan
- China
- Latin
America
- Brazil
- Mexico
- MEA
- South
Africa
- Saudi
Arabia
About Grand View Research
Grand View Research, Inc. is a U.S.
based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting services.
To help clients make informed business decisions, we offer market intelligence
studies ensuring relevant and fact-based research across a range of industries,
from technology to chemicals, materials and healthcare.
No comments:
Post a Comment